At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Baricitinib (drug), Placebo (drug)
- How long the study runs
- Study runs about 66 months (dates as stated)
- About the drug or intervention
- Baricitinib — drug: Administered orally · Placebo — drug: Administered orally
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 1 Year to 35 Years
- Who
- All
- Number of participants
- 150
- Started
- 2026-01-12
- Last checked
- 2026-10
Plain English Summary
What is this study?
- • Testing a new treatment for diabetes mellitus, type 1
- • Phase3 - 150 participants
- • The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D
Who can take part?
- • Ages 1 Year to 35 Years
- • Diagnosed with diabetes mellitus, type 1
Where?
- • Birmingham - Queen Elizabeth Hospital Birmingham
- • Birmingham - Birmingham Children's Hospital
- • Cambridge - Addenbrooke's Hospital
- • Cardiff - Noah's Ark Children's Hospital for Wales
- • +6 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 1 Year - 35 Years
- Who can join: All genders
What the study is looking for
- ✓Have Stage 1b or Stage 2 type 1 diabetes
- ✓Have a body weight of ≥8 kilograms (kg) (18 pounds) at screening
Who cannot take part
- ✗Have any other type of diabetes
- ✗Have uncontrolled high blood pressure
- ✗Have had a heart attack, heart disease, stroke, or heart failure
- ✗Have a history or high risk of venous thromboembolism, lymphoproliferative disease or cancer
- ✗Have a current or recent clinically serious infection
See the full criteria
Where Is This Study? (10 UK sites)
Queen Elizabeth Hospital Birmingham
Birmingham B15 2TH, United Kingdom
Birmingham Children's Hospital
Birmingham B4 6NH, United Kingdom
Addenbrooke's Hospital
Cambridge CB2 2QQ, United Kingdom
Noah's Ark Children's Hospital for Wales
Cardiff CF14 4XW, United Kingdom
University Hospital of Wales
Cardiff CF14 4XW, United Kingdom
Queen Elizabeth University Hospital
Glasgow G51 4TF, United Kingdom
Royal London Hospital
London E1 1BB, United Kingdom
St. George's Hospital
London SW17 0QT, United Kingdom
The John Radcliffe Hospital
Oxford OX3 9DU, United Kingdom
Southampton General Hospital
Southampton SO16 6YD, United Kingdom
How to Get in Touch
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Sponsor contactCONTACT
Physicians interested in becoming principal investigators please contact
Sponsor contactCONTACT